Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET | Source: Y-mAbs Therapeutics, Inc. NEW YORK,…
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3…
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Associations 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:…
Fobi AI Provides Clarification On Total Holdings Previously Provided In The Companys Information Circular
December 06, 2024 20:43 ET | Source: Fobi AI Inc. VANCOUVER, British…
Fobi AI Provides Update on Current Cease Trade Order
December 06, 2024 20:34 ET | Source: Fobi AI Inc. VANCOUVER, British…
Voxtur Announces Amendments to Financial Statements and MD&A forQ3 Ended September 30, 2024
December 06, 2024 18:16 ET | Source: Voxtur Analytics Corp. TORONTO and…
Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC)…
VivoPower to host Annual General Meeting on December 30, 2024 in London
London, Dec. 06, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR)…